Incannex Healthcare

Incannex Healthcare EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Incannex Healthcare (IXHL) as of Oct 26, 2026 is -23.54 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -29.94 M USD — a change of -21.36% (higher).

EBITDA

-23.54 MUSD

YoY

-21.36%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Incannex Healthcare is 2025 -23.54 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Incannex Healthcare was 2024 -29.94 M USD. It decreases by -21.36% higher compared to the previous year.

The Incannex Healthcare EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-2.44 M USD
Jan 1, 2019
-958,800.00 USD
Jan 1, 2020
-2.63 M USD
Jan 1, 2021
-8.48 M USD
Jan 1, 2022
-10.81 M USD
Jan 1, 2023
-14.23 M USD
Jan 1, 2024
-29.94 M USD
Jan 1, 2025
-23.54 M USD
The Incannex Healthcare EBITDA history
YEAREBITDAYoY
-23.54 MUSD-21.36%
-29.94 MUSD+110.34%
-14.23 MUSD+31.71%
-10.81 MUSD+27.40%
-8.48 MUSD+222.17%
-2.63 MUSD+174.59%
-958,800.00USD-60.64%
-2.44 MUSD+9.05%
-2.23 MUSD+325.29%
-525,200.00USD-74.40%
-2.05 MUSD-66.24%
-6.08 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Incannex Healthcare Stock analysis

What does Incannex Healthcare do? Incannex Healthcare Inc develops medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for various medical conditions including obstructive sleep apnea, traumatic brain injury, and inflammatory diseases. The company operates with 28 distinct R&D programs and six ongoing clinical trials, focusing on treatments for conditions such as OSA, TBI, ARDS, COPD, rheumatoid arthritis, and anxiety disorders. Its portfolio includes specific clinical projects like IHL-42X for OSA, IHL-675A for lung and joint inflammation, IHL-216A for concussion and TBI, PSI-GAD for anxiety, and MedChew GB and MedChew -1401 for pain management. Incannex generates revenue through the development and potential commercialization of these pharmaceutical products, targeting healthcare providers and patients seeking innovative treatments for complex medical conditions. The company's primary revenue streams come from the progression of its R&D pipeline, with key products in clinical stages including IHL-42X, IHL-675A, IHL-216A, PSI-GAD, MedChew GB, and MedChew -1401. These products are developed for specific medical indications, such as obstructive sleep apnea, inflammatory lung diseases, rheumatoid arthritis, and pain disorders. Incannex's business model relies on securing funding through clinical trial partnerships and potential future licensing agreements with pharmaceutical companies, aiming to bring these therapies to market for patients requiring advanced treatment options. Incannex Healthcare Inc targets healthcare providers and patients in the pharmaceutical sector who are seeking novel therapies for conditions like sleep apnea, chronic pain, and inflammatory disorders. The company's diversified R&D portfolio, with six active clinical trials, positions it to address multiple unmet medical needs across various therapeutic areas. By focusing on cannabinoid-based and psychedelic medicine approaches, Incannex differentiates itself in the pharmaceutical market, aiming to provide innovative solutions for complex health challenges. Incannex Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incannex Healthcare stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Incannex Healthcare is -23.54 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Incannex Healthcare changed from -29.94 M USD to -23.54 M USD, representing a -21.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Incannex Healthcare since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Incannex Healthcare historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Incannex Healthcare

All Key Metrics — Incannex Healthcare